ACR 2026 RheumNow Day 2 Recap Save
Day 2 of ACR Convergence 2026. Our expert faculty will highlight key abstracts, emerging research, and clinical insights from the day’s sessions, offering perspective on what these findings may mean for rheumatology practice. Drs. Adela Castro, Antoni Chan, Eric Dein Moderator: Dr. David Liew
Transcription
This is an ACR twenty twenty six podcast coming to you from ACR in Orlando. Hope you enjoy it. Great rheumatologists go to great meetings like this. RoomNow Live twenty twenty seven is happening January 3031 in Dallas, Texas. Join your colleagues from across the country and around the world for an interactive, engaging, and practice changing event.
Go to roomnow.live to see the full program register today.
Hi, everyone. It's David Liu here again. I'm hosting the RheumNow, ACR Conversions twenty twenty six daily recap for day two. We're really in the midst of a very impactful and busy meeting. It's been a lot of fun and I'm joined by another three friends here today to talk through some very interesting happenings for the day.
So I'm going to go round the screen and introduce yourselves and where you're from. Anthony.
Hello. I'm Anthony Chan, a consultant rheumatologist from Reading, United Kingdom.
Eric.
Eric Dine. I'm a rheumatologist practicing in, Summit, New Jersey, here in Orlando.
And Adela.
Hi, I'm Adela Castro from University of Tennessee Memphis.
Fantastic. So, some really interesting stuff on, out there today. Eric, I think we'll start with you. What caught your attention, caught your eye, big changing kind of abstracts?
Yes. Definitely some interesting sessions at the plenary today. I'm gonna chat about abstract eighteen twenty with what I found somewhat surprising results, so I'm interested to hear what people think. I thought very thought provoking. This was looking at cardiovascular risk with gout, something we've heard about in prior meetings.
This was the post hoc analysis of the CARES trial, which looked at the associated gout flares with subsequent cardiovascular disease, a big trial of over six thousand patients starting on urate lowering therapy. So taking a step back, we know gout is associated with metabolic syndrome. We know that there's mortality, cardiovascular risk associated with a gout diagnosis. There was a prior JAMA study in 2022, which showed an increased mortality rate of MACE after a gout flare. I think that's something that gets quoted a lot, that there's an odds ratio of almost two in the sixty days after a gout flare, and that extends out to one hundred and twenty days after a gout flare, that your risk of cardiovascular disease is elevated.
This was looking at a similar, you know, similar outcomes, but from a little bit different trial design, and so this was looking at this large population of patients started on either febuxostat or allopurinol, all patients with established cardiovascular disease, or I'm sorry, established risk factors for cardiovascular disease, and looking to see do they have gout flares and most importantly, were there MACE events? So the, this study differed from the prior study. So the prior study only defined a gout flare, defined it retrospectively looking at, you know, was there an ICD diagnosis code and were they prescribed therapy, including colchicine, NSAIDs and or corticosteroids, this one had a little bit more detailed analysis and perspective following of the patients. So they looked at both participant reported FLAIR or something called the GAFFL criteria. The GAFFL criteria was, includes three out of four criteria are needed, which includes a patient defined FLAIR, a pain of at least three out of 10 at rest, a swollen joint, or a warm joint.
So three of those need to be there. So it's a little bit more definitive of a diagnosis, and it's not based upon the medications. This was a nested case control study. This is the post hoc analysis of that prior trial that was looking at urate lowering therapy initiation. And so this study did not show that there's any increased risk of cardiovascular disease, MACE event after the patient had gout attacks.
And they looked at it in all different ways. No difference after self reported flare, no difference after the GAFA criteria. All the sensitivity analyses looking at physician adjudicated flares as definite or probable or just definite, swelling, warmth, any way they sliced it, they saw no difference in MACE events. So this large study initiation of urate lowering therapy, that there was not an increased difference. So what do we make of it?
I'm interested in what the group has to say. It is more detailed information, and it does make me think perhaps it wasn't really the FLAIR itself. You know, the last study was really based upon the medications and wasn't more the NSAIDs and more the steroids that increases it. So my takeaway is number one, it is safe to start patients on the ear rate lowering therapy with cardiovascular risk, even if we know that has a increased risk of FLAIR. And number two, you know, again, being cautious with the medications, but I think ultimately we need a little bit more data for this.
Yeah, and I mean this is really quite high fidelity data really. We're talking about data from Cares, really well run study. We're talking the people running this, I mean this is Cherry Yokosse and colleagues from, Mastgen Brigham, you know, the... Haiyun Choi, Dan Solomon, Sara Tadeski, you know, real kind of, people who you trust. If you're gonna trust anyone in this world to analyse these kind of data, these are the people you trust and to be able to to kind of turn around that JAMA finding is is pretty important.
So, maybe, Eric, can you just kind of go go into a bit more detail as to you were saying about the therapies from the previous analysis NSAIDs, steroids, two things we know have a lot of cardiovascular potential there. How do you tease that out? Aren't they just kind of inherent to the way in which we deal with gout flares or are we, I guess, thinking about colchicine as well and where that sits?
Yeah, I'd be really interested to go back into the other study and look at, was the colchicine group different from patients that were on NSAIDs or steroids? And I don't know, I'd have to look back to see what kind of analyses were done in that prior study. But, you know, definitely we know that there's risks associated with that. But, you know, I've always been counseling patients that the inflammation of gout itself is a risk factor, and I think, you know, certainly chronic inflammation is a risk. So, you know, but I think the question is, is a single gout attack, is that inflammation risk factor?
And I do think it is important to go back into, you know, what's the risk of, we know risks associated with one course of corticosteroids increase that risk, and how much of that was driving that other study over the course of NSAIDs. So I think it would be really good to understand that data from the other one more, and I wanna go back and look at that.
Yeah, absolutely. And I mean, it gets to the, like you say, this idea of trying to think about how we manage cardiovascular risk in gout in general in gout patients. Adela I mean how do you see these data in terms of your practice? I don't know does this change the way in which you approach that cardiovascular management piece for gout patients?
So I agree with Eric here. Definitely I want to know a little bit more about details in terms of the effects of colchicine, because we do know there's some evidence that colchicine may have some cardiovascular protective effect there. That will be interesting to see. Definitely am very aggressive with my gout patients because not only they have gout, but also gout is a marker of metabolic disease. So definitely these patients have more than just one risk factor, diabetes, obesity, hypertension.
So definitely those are factors that need to be managed appropriately, and of course, we need to manage gout appropriately. So I tend to manage my patients very aggressively and try to minimize cef flares. Definitely that's good to hear on this side in terms of the patients that were on ULT probably had less cardiovascular, major cardiovascular events.
Well, interesting stuff to take away to the clinic. I'm sure there's a lot more that we can do better with gout, we will see a little bit more later in this meeting, which is going be very interesting. But maybe I can throw to you now Adela about what you found interesting today. I think we're talking a bit about some guidelines that you saw.
Right, so a of interesting stuff today. My favorite, which was very needed, was the 2026 ACR SSA in Spartan Guidelines on Management for Axial Spondyloarthritis. I'm going to try to summarize the major hallmarks, what are the things that they added this time. So in terms of assessment of suspected axSpA, of course, they still remain getting the history, the labs, and then, of course, having that, particularly for extra axial manifestations, have those characteristics in mind. And then for the first line imaging, they recommended specifically getting the anterior pelvis x-ray with an AP view, just single view, as opposed to the previous one of the Ferguson views.
And then if that was negative, then the recommendation was to obtain the MRI. And this is something that is very high yield right now because they were very specific about the MRI, the optimal acquisition protocol, which guides a little bit more how to make the right diagnosis for axSpA on MRI. And something that's also interesting that they include in this guidance, if you have, for some reason, do not have access to MRI, then you can actually use low dose CT to diagnose patients with axSpA. So once you have a diagnosis, then how do you manage? And I think this is, to me, still very controversial a little bit, but they were saying that the recommendations this time included if the patient had no risk factors for progression, meaning normal CRP, nosenthesmophytes, then you can still consider NSAIDs as first line.
Then they were very vague about it, but this time they included a recommendation specifically for COX-two inhibitor NSAID as opposed to the other ones, and they, of course, recommend continuous NSAID use as opposed to intermittent or PRN. But if the patient had high risk for progression, then in this case, you could start a patient on TNF inhibitor in a junction, of course, with the other therapies that are very important, like physical therapy, which they also make a recommendation about it. Specifically, they recommend aquatic therapy over land therapy. I was like, it's very important to keep that in mind. And then, of course, then assessment and once you start to decide to start patient biologic, then before they were recommending TNF first, but now there's no difference.
You pretty much between TNF inhibitor or IL-seventeen inhibitor, whichever you have access to, of course, and take into consideration what other comorbidities the patients have that need either medication. And then something that also caught my attention for the first time also in terms of patients that are difficult to treat, because sometimes those were very vague in the previous guidance, but then this time we have a bit more recommendation on difficult to treat patients. This time they also recommended the evaluation of nociplastic pain and even some guidance on how to manage nociplastic pain, and then they also recommended specifically this time if the patient is really difficult to treat because of comorbidities or anything else, they do recommend this time combination biologic. So this was something that was also of a highlight, especially because there's limited evidence of combination biologic or combination targeted therapies. But the fact that they mentioned this in this guideline is also very helpful to explore more on this.
So I try to cut it down in a nutshell, but I want to hear your thoughts about it.
I mean, you hit some very interesting Thank points you for cramming that all in. And fascinating that in kind of these anticipated guidelines, and guidelines are usually fairly conservative that all of a sudden that we've had a swing out with combination biologics, which I guess speaks to how mainstream the idea is becoming. Anthony, you're my font of knowledge as far as the therapeutic approach is concerned. I turn to you often. So tell me a little bit, is this expected, the approach that I guess having TNF and IL-seventeen are the same, on equal footing, that's quite interesting.
Are these guidelines more or less what you thought?
Yeah, think we have now got the ASAS guidelines, and I was involved in The UK BSR guidelines, and now we have the ACR one. And I think it's emerging evidence when these guidelines are written what's available at the time. But some interesting thing, they are going for more risk stratification type approach where are you a fast progress or a low progressor? Then in the second phase, do you meet criteria for difficult to treat or difficult to manage? So it's a more individualised type approach, which I think is the right thing to do.
They also allow choice here between TNF, Jack or IL-seventeen and even combination. So this is I think it's an evolving thing. Think the guidelines will evolve as the evidence evolves. And so I think it's a kind of the right approach. The NSAID one is interesting because that's kind of come back again.
And we have this constant discussion whether on demand versus continuous is better. We've been through that many times. But I think it's good that it's put out there as an option again.
For me, was particularly the NSAID. These are usually young patients and not that much compliant with pills, and you really want them to get into remission. So of course, NSAIDs help quite a bit with the pain pretty quick, so probably as a adjunctive, but I am a little bit hesitant on just keeping my patients on just NSAID, even if they are low risk. I think I'm a little bit more nervous if they don't take the medication, how to monitor them closely.
Yeah, think with these patients, you have to monitor them. The other thing is access to MRIs. How often can you do these things if you are putting somebody on a drug that potentially where the disease could progress? You also mentioned about low dose CT. So that's also a nice paper today that showed an abstract today that showed that it probably was a bit more sensitive than MRI in terms of picking structural progression.
Of course that's difficult because of the radiation that's involved if use that as your measure. But there's no doubt it was better than the plain radiographs and perhaps even better than the MRI.
Eric, you've got a bit of interest in how this imaging plays out. Did this kind of surprise you a little bit, some of the recommendations from here? Or do you think actually, is this really the start of better phenotyping as well from imaging? That's a part, I think, a big theme of where we're going.
Yeah. I think... I mean, phenotyping, understanding, think really classifying, again, who's at risk, what their profession is, understanding these, you know, radiographic, non radiographic. I think I was gonna say just kind of more generally, the guidelines help us decide how to practice clinically. It's also just useful for access, and so in, you know, for those of us in the American system often needing to justify the idea that they put out guidelines saying TNF inhibitors and IL-seventeen can be considered equally, and particularly that combination biologic is a guideline directed recommendation, I think, can be really helpful just in terms of getting the access to these medications.
And so that was, I think, actually the real world practical part that I thought can really change our practice.
Something about injection in particular that, of course, caught my attention in the guidance, is kind of like the hot topic of today, which is like, how do you identify what is the MRI defining of axSpA? Then in the guidance, they were like, Make sure that you use this protocol, but they don't mention the specific protocol, which I think is important that it needs to be widespread. But again, this protocol has its limitations because this protocol was made on using central readers, but then we already know we don't have all the time expert radiologists reading our MRIs. Definitely we have to be in that contact with radiologists, make sure we are asking specific questions.
There's a huge weighting now on imaging in terms of classification of XBA because of the new ASA Spartan guidelines. I think this is why today in the plenary they also presented the Spartan SSR and they call it MRI indicative of XBA. That's the new definition where there's a bit more weighting on erosions compared to the old ASAS guidelines where it was more inflammation. So I think that's going to influence how we classify patients for clinical trials. But lots of posters around where they have found that it actually does exclude a lot of people in some countries where they don't have similar access to MRI.
Let me quickly throw in the one question that I feel like this has to be our first mention of AI for the day, won't be our last. Is AI axiomotor imaging, going to change a little bit
of this? Is that going
to help us to phenotype? And all of a sudden we've got all these choices, we were changing all the guidelines, they were very boring for a long time, all of a sudden things are really front foot. Does that help to unlock, I guess, lot of our personalization?
I think there is this issue with standardization central That could be a role for AI to adjudicate between different readers where then you have a standardised approach to that. And in places where you don't have specialised radiologists to actually do some of this, that could again potentially be a place where this can be done. But it still needs human validation at the end of that.
Yeah. Think Oh, sorry. No. Go ahead. Go ahead.
I I think, again, it's... I I agree with what you said. I think some places just don't have experience readers, and and AI will definitely bring the experience of having looked at a lot of them. It'll be interesting to see, as AI gets better and better, will it be picking up these microerosions that are extremely sensitive, and and what does that mean for, you know, clinical relevance of them? So it'll be interesting because as it gets better and better, I wonder if this sensitivity might just produce, you know, more results that we then have to decide what to do with.
-Yeah, I agree that definitely imaging is important for diagnosis, specifically for our early patients, which is what we want to get them. And then, of course, having a good MRI result that we can trust is going to be very important. I think not only, of course, the radiologists need to have the education, but also ourselves as rheumatologists that are in charge of actually making the diagnosis, then it's going to be important to kind of understand what exactly is that we're looking for, or if we don't have those results, we're not sure, we definitely want to communicate with our radiologists.
So before we move on, just want to finally ask, of the three of you, who's using combination biologics? Know, yeah?
Yeah.
You've got one take. So yeah, yeah. I mean, I think that's all, yeah, everyone here. So maybe tell us about how... I think it'd be interesting to hear thoughts on where people think this is going.
Clearly, it's not going to be for everyone. Clearly, there are some people who will benefit. How do we pick the winners? How is it playing out in your practice?
So for me in particular, the most common situation when I find myself needing to use combination biologics is when I have patients with concomitant poorly controlled inflammatory bowel disease, you know? And so far, I've been doing very well so far, kind of like with as the evidence has been showing, the combination with the IL-twenty three inhibitors with the TNF. So, so far, that has been quite a success, but sometimes I've also been needing to use JAK in combination with IL-twenty three or TNF as well. And of course, we definitely need more data on safety. But so far, the data we have on safety seems pretty safe, so we'll have to see more.
Yeah, there was the study from the Spanish and the French groups here at ACR yesterday and today, I think replicates what we've seen at previous ACR and EULA, that generally it's quite safe. I think that's because of careful selection with these patients that's why it's turned out to be like this. And a lot of what we do is in combination with dermatologists or gastroenterologists. We're doing it within a combined clinic setting where we have decided that we would go for combination therapy. But I think it will become more common.
Fascinating how it's flipped from when we were in RA and TNF inhibitors and anachyma that didn't work out and then we for so long flipped away from this is completely prohibited on the label and now I feel like the move in spa has emboldened the rest of rheumatology and we haven't quite hit our safety barrier yet. It will be a very interesting one to see how it plays out. Anthony, tell me a little bit about what you saw that was good on the floor today.
So I think this ACR is focused on obesity and BMI. It's heavily, I can use the word, weighted on that. And so a lot of studies. But I was interested in thirteen oh five. And this is the bimekizumab data because it's a large data set.
What they did is they pulled the B optimal, B complete, and B vital. Now we know that in PSA, forty percent of people, PSA patients would be classified as obese or overweight. So in this study they had about one thousand patients who received 160mg Bisikizumab every four weeks. And they followed them up for three years, And the ACR50 was then divided up to whether they were the BMI of less than thirty or more than thirty five. And though people who had a BMI of greater than thirty five at one year, the ACR50 was 41 compared to the lighter group, which achieved fifty seven percent.
And at three years, that number remained the same. It didn't change after three years. We would expect that if you had achieved an ACL50, maybe you became more active, you could do more things. But in fact, it didn't change in that time. The percentages remained the same.
So it was static three years based on your initial BMI. And what's striking is the gap between those who had BMI of thirty five and those who had BMI of thirty. It was somewhere between a 17 percentage point difference between the two. Now of course, we will see the fifty two week data to get a PSA on the last day. But there is this whole we knew this for a long time that the higher your BMI, you poorer the response from biologics.
But this one shows you that not only that, you stay within that same class even three years down the line. So this calls for another approach that we would look at maybe in GLP ones in these people who have then achieved ACR50 that the combination would be a metabolic approach to treating them in terms of getting them further down on their tender, swollen joint counts.
And I mean this is, I guess, we've always seen this in our practice. I think now that we've got something that we can actively do about it, well I mean there's more options to think about what we can do about it, All of a sudden, I think we're starting to realize what we might be able to do. And I guess we're starting to be more concerned about the the... Where the causal relationship sits. So, Anthony, just speculate a little bit here for me.
It's, you know, this a safe space. It's only the entire internet listening to you. Just tell me what you think the breakdown how the causal relationships might sit here. You know, I think we're trying to I know we're trying to interpret things through post hoc analyses, registration data aren't necessarily meant to set up to answer these questions directly. But what's this relationship between weight and disease activity, pharmacotherapy activity?
How do you see it?
So what is quite clear from this data here today and also from the Together PSA data, which will be presented later in the conference, is that treating inflammation alone is not enough for us to not only achieve better joint outcomes, but also the weight loss. So when these people achieve ACR50, their weight still remains sometimes the reduction of the weight is not as significant as we think, that by getting them into good disease state that they may exercise more. So there is clearly a metabolic pathway here. So the incretins are doing something on adipocytes which we know are pro inflammatory. So it's not just the weight that is causing joint loading here but it's actually an inflammatory cascade here that I think that's at work.
Because if you look at the Tiguanip PSA data, now they didn't have a tisepatide alone arm in that study, but you could read from the combination versus isekizumab the alone that there's a 12 percentage point improvement. So every 100 patients, there are twelve other people who improve in terms of their joints just being on the extra GLP ones. So that's where we are going. So it's not just all inflammatory. And this brings up the whole thing that all these non inflammatory issues that we are discussing about difficult to treat, difficult to manage, While we are trying to understand all of that, I think this is here is potentially an avenue for us to go and explore in terms of the non inflammatory aspects of PSA.
Fascinating, fascinating stuff. Let's move on to the, well actually sorry, does anyone have any kind of, I mean this is something that's a very live thing in our practices. Eric, I mean, thinking about, I guess, how we're treating, our PSA patients, approaching our PSA patients. I mean, has this all changed the way that you counsel your patients and the way that you, I guess, approach this management approach? And I'm interested for Adela as well.
Very kind of different parts of the country, I think different perspectives are really important.
Absolutely. I think, you know, number one, I think just like gout, PSA is also a metabolic disorder. And so it is with hypertension, hyperlipidemia, diabetes, gout, PSA, I think are all in that same umbrella that we should think of cardiovascular risk just as we talked about with the first topic. It all is under one umbrella. And I think we need to not just focus on the joints and the skin, we need to think about it globally.
And number two, I think all this data and the Together PSA, and we now need to think about GLP-one or just weight reduction as disease modifying therapy. And I think that's true for osteoarthritis we've seen at this talk and for inflammatory arthritis and for nearly all of our conditions are touched on that addressing the weight is potentially disease modifying for a lot of these conditions.
And Adela, is that kind of, I guess, probably is pretty similar to... I I can imagine that it's pretty similar to the Paratroote.
I agree. And then the counseling is very important. I was actually talking to one of my colleagues when they came out of the session on the GLP and psoriatic arthritis, they were like, Counseling the patients, you may want to do it with a grain of salt. You may want to ask permission to the patient if you want to counsel them on obesity, which are, how often do you ask permission to counsel your patients? That was interesting to hear from that session.
And then I think it's important, and this is definitely something that is helpful to have because we do have that modifiable risk factor that not only causes inflammation and for so long was related to poor outcomes in those patients. Now we do have a tool to modify this risk factor. And of course, when we do see the weight loss, patients are a little bit more energetic, they have more ways to exercise. So that of course, changes a little bit of everything. It not only helps with their actual inflammation, but it also helps with, as Anthony was saying, the non inflammatory part, the depression, the neuroplastic pain, all of them.
Yeah, it's tricky. I mean, I think it's easy to offend in these situations and different people have very different perspectives to that. And if you get people offside over the first question, then you're not going to have much luck with the rest of the conversation. That opening is very important. So, I just want to talk a little bit about, you know, kind of in the same theme, but then a very much a right turn, talking a little bit about, I guess, what traditionally have been spa related therapies and how they're taking from PMR and GCA.
And there's there's some really good reasons for that. I guess, you know, we've been really focused on the Th one access previously and hence, tocilizumab, IL one... IL six, and I guess, you know, when we've kind of looked into IL-one kind of related therapies, but also I guess thinking about things like upadacitinib, where we know it's going to cover that. But then in recent times, there's been a bit of a shift. Well, I mean, it's always been there, but I think there's been a greater attention success breeds attention, to IL-seventeen, twelve twenty three focused therapies in the PMR and GCA space.
So one of the abstract in the PMR GCA abstract session, there are two, really interesting abstracts on that. Firstly, I think it was... It's a follow on data from the REPENSH study. A lot of us will be aware that REPENSH, secukinumab in, relapsing PMR came out early in the year. It's very much looking, it's looking quite good.
I think it's going to lead... You know, it's all going to lead to to real world use in the very near future, in multiple jurisdictions. What this looked at is, and I think this is always a question with, supposedly, phasic disease, sometimes phasic disease, like PMR, relapsing PMR, maybe, less phasic. What happens when you stop the therapy? And so in Replenish, after the first fifty two weeks, last act of therapy was at forty eight weeks, but you should still be on steady state at that point at fifty two weeks.
They stopped in both arms the placebo and the active therapy. What happened? Well, fifty percent of people flare in that situation. Shock horror, a relapsing PMI a chronic disease a lot of the time. But then, I guess, does secukinumab give you a legacy effect?
And there's a delta AUC between the two curves, there's a difference, but really it's possibly just maybe drug wearing off, maybe there's some limited legacy effect. I think we've got to dig into that a little bit more. Of course, ideally what we'd like to do is kind of hit people with a therapy and have an effect that goes beyond, but we may be stuck in a situation where we're giving people secukinumab in the long term, much as we would for RA and Axbar and PSA, and once upon a time people thought that they wouldn't thought the idea of giving ongoing therapy for PSA was ludicrous and we've come a long way since then. Know, all of sudden we're talking about all sorts of things. So the second part of that is actually in the same vein, ostokinamab in GCA.
And actually I remember some years ago watching our friend and colleague Richard Conway on the late breaking plenary stage talking about his study looking at patients who received osakimab for GCA. It looked very promising. There, there was a small, series from, from MassGen which looked a lot less promising. So in that context, the French have done a phase 2b investigated, initiated study because it's a patent randomized controlled trial, first time it's proper RCT data, and what you can see is that it's slow to kick in, you know, ustachianumab can be a bit slow to kick in, but there's definitely a wide gap between the con... Between the con...
The the placebo and the... And the isekindamab arms. So it's really interesting, in the context that THEA, c h e I a, study, which was geselkumab, the twenty three p nineteen inhibitor, in GCA was a bit of a bust, earlier this year. So I guess there's all sorts of questions. Is is IL twelve doing the heavy lifting?
Is there something different about this? Is it partially about study design? And will a phase three investigator initiated study actually happen? So let me kind of ask all three of you, first of all, are any of you using biologics at all for, PMR? And I guess this is a thing now, we've obviously got some options, we've got cirilimab in The US.
Right, and you know, and I love this because we also had like a great lecture from Mike Potman, of course, about this. And then there's still particularly the REPENISH and the saraholumab trial were all on relapsing disease. So technically, you really kind of have difficulty tapering the steroids. But in my clinical practice, these are patients that are already having so many comorbidities like diabetes, have very high risk for osteoporosis, and then do I want to wait to taper down the steroids that long? So having the access of biologic and having the option of starting biologic early and decrease the steroid burden for me is life changing, and it's also for my patients.
At the same time, having more than one option because I've had that patient where the patient, she did have a side effect to sorrelimab, and then I was like, What can I do now? But then now we do have other options that I can start my patients on. So definitely having that option of biologics for these patients is great.
Yeah, and I mean, you know, I think it is entirely possible we might have more options in the future in relapsing PMR. There's been a couple of things thrown around at this meeting, then I guess getting to your point as well, newly diagnosed, if we can get in there. Who knows, maybe it's all to do with yesterday we talked about generic tofacitinib and getting it from cost plus drugs and all the rest. Who knows what that might do? There's obviously some data there.
Great. So maybe we'll just quickly, time is getting upon us. Let's do a quick fire round around the grounds here, about some... Just an interesting thing that you saw out there. I'll start with, you, Eric.
Yeah. So yesterday, you you talked a lot about some of the new mechanisms for for myositis and particularly dermatomyositis. But I I think to zoom in on brepasinib, which is now FDA approved in The US, That is something that is available for us now, the TYK2 JAK inhibitor. There's a range of different posters on it, fifteen eighty four to fifteen eighty seven, and just a few quick hits from those. One of looked at skin.
Improvements began at week four, improvements of CDASI, itch scores, skin related quality of life. Another one on steroids, looking at the subgroup that three quarters of the patients entered the study on steroids. Those patients did well. They were able to taper the steroids. They looked at the subgroup that had interstitial lung disease.
One fifth of them had baseline ILD. They didn't specifically look at any ILD endpoints, so I can't comment on that. But it seemed to be safe in ILD patients. There wasn't any kind of signal for ILD progression, so I think definitely more information needed there. And then the fourth poster was looking at patient related outcomes, and the PROs looked favorable for functional disability, pain, and fatigue.
So I thought that was useful data for something that is now on the market for us.
Yeah, very exciting. Adela?
So I am going to go on that same note of the hot topic of GLP-one. So this one, this is abstract eighteen ninety eight, and in this study, the objective was to evaluate the association between GLP-one receptor agonists in patients with rheumatoid arthritis that were on DMARDs, particularly on methotrexate and TNF inhibitors, and they wanted to evaluate the risk of malignancy in five years. In specific malignancies that they were kind of high yield here were lung cancer and non Hodgkin lymphoma. This was a retrospective study using the TriNetX database, including over twenty four thousand patients with rheumatoid arthritis, and they did propensity score matching to make it even, so each cohort had over twelve thousand patients. And then in the study, it ended up showing that it seemed like patients that were on GLP-one, that had rheumatoid arthritis that were on GLP-one agonist had some decreased chances of having lung cancer and non Hodgkin lymphoma.
However, when I went a little bit more into it, definitely there was a lot of confounding. Specifically, we do know that malignancy at risk in patients with rheumatoid arthritis comes from disease and disease activity and smoking, so I didn't see mentioned about the smoking adjustment, but they didn't mention specifically the amount of smoking, active smoking, and of course they didn't include disease activity, so definitely a lot of confounding. Then, of course, a little bit of selection bias because patients that are on GLP-one agonist, probably they have more healthcare access or probably more monitored, things can be a little bit taken care of better than the ones that don't have the access. For me, was like, yeah, part of the hot topic, but I cannot make a conclusion on this yet.
Well, are very, I mean, they're very pertinent everyday questions that we need to figure out the answers for if we're going to start using a lot of GLP-1s and incretin therapy in RA, I guess, well. I think maybe one of the themes of of this meeting and others has been a lot of TriNetX. Some of it data, some of it's done well, some of it's done less well. I think this was, this was good, but I think at the same time it still just generates questions, more questions than answers sometimes. Anthony?
Yeah, these are hypothesis generating studies. They make us think about them, but I don't think we can definitely draw a line on them for the reasons that you described, Adela. They haven't matched for severity of smoking. I must talk about AI because no talk is complete without some AI. So I've gone for thirteen forty eight which is a nice study from Columbia where they looked over nearly twenty five years of their electronic health record and they used CHET GPT-four, approved, to see whether they could fish out of four point five million total number patients how many people had PSA.
And they gave them 27 features of PSA so that they could pick out how many people met CRISPR criteria. Now we always had this hype that we could use this to identify people for clinical trials or treatment. If you give them the guidelines they'll tell you how many people they have. So at best only forty three percent of these PSA patients they could say they met Casper criteria. They could pick up psoriasis.
They could pick up inflammatory arthritis. What they couldn't pick up is the disease activity. Only five percent of them had enough information for the dapsa and only five percent had joint counts. So the message is if you want to use AI in the future, we better record these things in our EHR. Otherwise, the data has got no use for us later on.
So that's, I think, the key message here. The AI can read your notes but depends on what's what's in your notes.
Absolutely, absolutely. And so my final one going along that same idea of a bit of AI and I know that Anthony's got one of these, you know, kind of... It's not quite in your cupboard, but you've got it in in the back of your office is Arthur Diana, the muscular skeletal ultrasound AI driven robot. Seen a little bit of this. It's been very interesting, how it's all played out in Europe.
This is the first independent evaluation that was done in Sweden, at Linkoping. What they did is they looked at 99 patients, 22 joints in wrist, hands, in the 28 joint count, and they 21, sorry, they got eighty six percent acquisition rate. So it's pretty good. I think the accuracy something that's yet to be determined. I think we look forward to seeing data around that.
Have you been having fun with yours, Anthony? Your machine?
We're having great fun. We are collecting data, but I think the performance is improving year on year. We've been to this, you've written on this as well in previous years, so I think it's certainly a help to us in terms of our decision making. It doesn't replace the rheumatologist, but it does help us gain time because we would otherwise be scanning these patients ourselves.
Absolutely, and time is what we all need. Speaking of which, we are at time. It has always been a pleasure. It's always a pleasure speaking to the three of you. Thank you very much for joining me, Anthony, Eric, Adela.
Have a great night. Thank you so much.
Thank very much.
Thanks. Thank you.
Go to roomnow.live to see the full program register today.
Hi, everyone. It's David Liu here again. I'm hosting the RheumNow, ACR Conversions twenty twenty six daily recap for day two. We're really in the midst of a very impactful and busy meeting. It's been a lot of fun and I'm joined by another three friends here today to talk through some very interesting happenings for the day.
So I'm going to go round the screen and introduce yourselves and where you're from. Anthony.
Hello. I'm Anthony Chan, a consultant rheumatologist from Reading, United Kingdom.
Eric.
Eric Dine. I'm a rheumatologist practicing in, Summit, New Jersey, here in Orlando.
And Adela.
Hi, I'm Adela Castro from University of Tennessee Memphis.
Fantastic. So, some really interesting stuff on, out there today. Eric, I think we'll start with you. What caught your attention, caught your eye, big changing kind of abstracts?
Yes. Definitely some interesting sessions at the plenary today. I'm gonna chat about abstract eighteen twenty with what I found somewhat surprising results, so I'm interested to hear what people think. I thought very thought provoking. This was looking at cardiovascular risk with gout, something we've heard about in prior meetings.
This was the post hoc analysis of the CARES trial, which looked at the associated gout flares with subsequent cardiovascular disease, a big trial of over six thousand patients starting on urate lowering therapy. So taking a step back, we know gout is associated with metabolic syndrome. We know that there's mortality, cardiovascular risk associated with a gout diagnosis. There was a prior JAMA study in 2022, which showed an increased mortality rate of MACE after a gout flare. I think that's something that gets quoted a lot, that there's an odds ratio of almost two in the sixty days after a gout flare, and that extends out to one hundred and twenty days after a gout flare, that your risk of cardiovascular disease is elevated.
This was looking at a similar, you know, similar outcomes, but from a little bit different trial design, and so this was looking at this large population of patients started on either febuxostat or allopurinol, all patients with established cardiovascular disease, or I'm sorry, established risk factors for cardiovascular disease, and looking to see do they have gout flares and most importantly, were there MACE events? So the, this study differed from the prior study. So the prior study only defined a gout flare, defined it retrospectively looking at, you know, was there an ICD diagnosis code and were they prescribed therapy, including colchicine, NSAIDs and or corticosteroids, this one had a little bit more detailed analysis and perspective following of the patients. So they looked at both participant reported FLAIR or something called the GAFFL criteria. The GAFFL criteria was, includes three out of four criteria are needed, which includes a patient defined FLAIR, a pain of at least three out of 10 at rest, a swollen joint, or a warm joint.
So three of those need to be there. So it's a little bit more definitive of a diagnosis, and it's not based upon the medications. This was a nested case control study. This is the post hoc analysis of that prior trial that was looking at urate lowering therapy initiation. And so this study did not show that there's any increased risk of cardiovascular disease, MACE event after the patient had gout attacks.
And they looked at it in all different ways. No difference after self reported flare, no difference after the GAFA criteria. All the sensitivity analyses looking at physician adjudicated flares as definite or probable or just definite, swelling, warmth, any way they sliced it, they saw no difference in MACE events. So this large study initiation of urate lowering therapy, that there was not an increased difference. So what do we make of it?
I'm interested in what the group has to say. It is more detailed information, and it does make me think perhaps it wasn't really the FLAIR itself. You know, the last study was really based upon the medications and wasn't more the NSAIDs and more the steroids that increases it. So my takeaway is number one, it is safe to start patients on the ear rate lowering therapy with cardiovascular risk, even if we know that has a increased risk of FLAIR. And number two, you know, again, being cautious with the medications, but I think ultimately we need a little bit more data for this.
Yeah, and I mean this is really quite high fidelity data really. We're talking about data from Cares, really well run study. We're talking the people running this, I mean this is Cherry Yokosse and colleagues from, Mastgen Brigham, you know, the... Haiyun Choi, Dan Solomon, Sara Tadeski, you know, real kind of, people who you trust. If you're gonna trust anyone in this world to analyse these kind of data, these are the people you trust and to be able to to kind of turn around that JAMA finding is is pretty important.
So, maybe, Eric, can you just kind of go go into a bit more detail as to you were saying about the therapies from the previous analysis NSAIDs, steroids, two things we know have a lot of cardiovascular potential there. How do you tease that out? Aren't they just kind of inherent to the way in which we deal with gout flares or are we, I guess, thinking about colchicine as well and where that sits?
Yeah, I'd be really interested to go back into the other study and look at, was the colchicine group different from patients that were on NSAIDs or steroids? And I don't know, I'd have to look back to see what kind of analyses were done in that prior study. But, you know, definitely we know that there's risks associated with that. But, you know, I've always been counseling patients that the inflammation of gout itself is a risk factor, and I think, you know, certainly chronic inflammation is a risk. So, you know, but I think the question is, is a single gout attack, is that inflammation risk factor?
And I do think it is important to go back into, you know, what's the risk of, we know risks associated with one course of corticosteroids increase that risk, and how much of that was driving that other study over the course of NSAIDs. So I think it would be really good to understand that data from the other one more, and I wanna go back and look at that.
Yeah, absolutely. And I mean, it gets to the, like you say, this idea of trying to think about how we manage cardiovascular risk in gout in general in gout patients. Adela I mean how do you see these data in terms of your practice? I don't know does this change the way in which you approach that cardiovascular management piece for gout patients?
So I agree with Eric here. Definitely I want to know a little bit more about details in terms of the effects of colchicine, because we do know there's some evidence that colchicine may have some cardiovascular protective effect there. That will be interesting to see. Definitely am very aggressive with my gout patients because not only they have gout, but also gout is a marker of metabolic disease. So definitely these patients have more than just one risk factor, diabetes, obesity, hypertension.
So definitely those are factors that need to be managed appropriately, and of course, we need to manage gout appropriately. So I tend to manage my patients very aggressively and try to minimize cef flares. Definitely that's good to hear on this side in terms of the patients that were on ULT probably had less cardiovascular, major cardiovascular events.
Well, interesting stuff to take away to the clinic. I'm sure there's a lot more that we can do better with gout, we will see a little bit more later in this meeting, which is going be very interesting. But maybe I can throw to you now Adela about what you found interesting today. I think we're talking a bit about some guidelines that you saw.
Right, so a of interesting stuff today. My favorite, which was very needed, was the 2026 ACR SSA in Spartan Guidelines on Management for Axial Spondyloarthritis. I'm going to try to summarize the major hallmarks, what are the things that they added this time. So in terms of assessment of suspected axSpA, of course, they still remain getting the history, the labs, and then, of course, having that, particularly for extra axial manifestations, have those characteristics in mind. And then for the first line imaging, they recommended specifically getting the anterior pelvis x-ray with an AP view, just single view, as opposed to the previous one of the Ferguson views.
And then if that was negative, then the recommendation was to obtain the MRI. And this is something that is very high yield right now because they were very specific about the MRI, the optimal acquisition protocol, which guides a little bit more how to make the right diagnosis for axSpA on MRI. And something that's also interesting that they include in this guidance, if you have, for some reason, do not have access to MRI, then you can actually use low dose CT to diagnose patients with axSpA. So once you have a diagnosis, then how do you manage? And I think this is, to me, still very controversial a little bit, but they were saying that the recommendations this time included if the patient had no risk factors for progression, meaning normal CRP, nosenthesmophytes, then you can still consider NSAIDs as first line.
Then they were very vague about it, but this time they included a recommendation specifically for COX-two inhibitor NSAID as opposed to the other ones, and they, of course, recommend continuous NSAID use as opposed to intermittent or PRN. But if the patient had high risk for progression, then in this case, you could start a patient on TNF inhibitor in a junction, of course, with the other therapies that are very important, like physical therapy, which they also make a recommendation about it. Specifically, they recommend aquatic therapy over land therapy. I was like, it's very important to keep that in mind. And then, of course, then assessment and once you start to decide to start patient biologic, then before they were recommending TNF first, but now there's no difference.
You pretty much between TNF inhibitor or IL-seventeen inhibitor, whichever you have access to, of course, and take into consideration what other comorbidities the patients have that need either medication. And then something that also caught my attention for the first time also in terms of patients that are difficult to treat, because sometimes those were very vague in the previous guidance, but then this time we have a bit more recommendation on difficult to treat patients. This time they also recommended the evaluation of nociplastic pain and even some guidance on how to manage nociplastic pain, and then they also recommended specifically this time if the patient is really difficult to treat because of comorbidities or anything else, they do recommend this time combination biologic. So this was something that was also of a highlight, especially because there's limited evidence of combination biologic or combination targeted therapies. But the fact that they mentioned this in this guideline is also very helpful to explore more on this.
So I try to cut it down in a nutshell, but I want to hear your thoughts about it.
I mean, you hit some very interesting Thank points you for cramming that all in. And fascinating that in kind of these anticipated guidelines, and guidelines are usually fairly conservative that all of a sudden that we've had a swing out with combination biologics, which I guess speaks to how mainstream the idea is becoming. Anthony, you're my font of knowledge as far as the therapeutic approach is concerned. I turn to you often. So tell me a little bit, is this expected, the approach that I guess having TNF and IL-seventeen are the same, on equal footing, that's quite interesting.
Are these guidelines more or less what you thought?
Yeah, think we have now got the ASAS guidelines, and I was involved in The UK BSR guidelines, and now we have the ACR one. And I think it's emerging evidence when these guidelines are written what's available at the time. But some interesting thing, they are going for more risk stratification type approach where are you a fast progress or a low progressor? Then in the second phase, do you meet criteria for difficult to treat or difficult to manage? So it's a more individualised type approach, which I think is the right thing to do.
They also allow choice here between TNF, Jack or IL-seventeen and even combination. So this is I think it's an evolving thing. Think the guidelines will evolve as the evidence evolves. And so I think it's a kind of the right approach. The NSAID one is interesting because that's kind of come back again.
And we have this constant discussion whether on demand versus continuous is better. We've been through that many times. But I think it's good that it's put out there as an option again.
For me, was particularly the NSAID. These are usually young patients and not that much compliant with pills, and you really want them to get into remission. So of course, NSAIDs help quite a bit with the pain pretty quick, so probably as a adjunctive, but I am a little bit hesitant on just keeping my patients on just NSAID, even if they are low risk. I think I'm a little bit more nervous if they don't take the medication, how to monitor them closely.
Yeah, think with these patients, you have to monitor them. The other thing is access to MRIs. How often can you do these things if you are putting somebody on a drug that potentially where the disease could progress? You also mentioned about low dose CT. So that's also a nice paper today that showed an abstract today that showed that it probably was a bit more sensitive than MRI in terms of picking structural progression.
Of course that's difficult because of the radiation that's involved if use that as your measure. But there's no doubt it was better than the plain radiographs and perhaps even better than the MRI.
Eric, you've got a bit of interest in how this imaging plays out. Did this kind of surprise you a little bit, some of the recommendations from here? Or do you think actually, is this really the start of better phenotyping as well from imaging? That's a part, I think, a big theme of where we're going.
Yeah. I think... I mean, phenotyping, understanding, think really classifying, again, who's at risk, what their profession is, understanding these, you know, radiographic, non radiographic. I think I was gonna say just kind of more generally, the guidelines help us decide how to practice clinically. It's also just useful for access, and so in, you know, for those of us in the American system often needing to justify the idea that they put out guidelines saying TNF inhibitors and IL-seventeen can be considered equally, and particularly that combination biologic is a guideline directed recommendation, I think, can be really helpful just in terms of getting the access to these medications.
And so that was, I think, actually the real world practical part that I thought can really change our practice.
Something about injection in particular that, of course, caught my attention in the guidance, is kind of like the hot topic of today, which is like, how do you identify what is the MRI defining of axSpA? Then in the guidance, they were like, Make sure that you use this protocol, but they don't mention the specific protocol, which I think is important that it needs to be widespread. But again, this protocol has its limitations because this protocol was made on using central readers, but then we already know we don't have all the time expert radiologists reading our MRIs. Definitely we have to be in that contact with radiologists, make sure we are asking specific questions.
There's a huge weighting now on imaging in terms of classification of XBA because of the new ASA Spartan guidelines. I think this is why today in the plenary they also presented the Spartan SSR and they call it MRI indicative of XBA. That's the new definition where there's a bit more weighting on erosions compared to the old ASAS guidelines where it was more inflammation. So I think that's going to influence how we classify patients for clinical trials. But lots of posters around where they have found that it actually does exclude a lot of people in some countries where they don't have similar access to MRI.
Let me quickly throw in the one question that I feel like this has to be our first mention of AI for the day, won't be our last. Is AI axiomotor imaging, going to change a little bit
of this? Is that going
to help us to phenotype? And all of a sudden we've got all these choices, we were changing all the guidelines, they were very boring for a long time, all of a sudden things are really front foot. Does that help to unlock, I guess, lot of our personalization?
I think there is this issue with standardization central That could be a role for AI to adjudicate between different readers where then you have a standardised approach to that. And in places where you don't have specialised radiologists to actually do some of this, that could again potentially be a place where this can be done. But it still needs human validation at the end of that.
Yeah. Think Oh, sorry. No. Go ahead. Go ahead.
I I think, again, it's... I I agree with what you said. I think some places just don't have experience readers, and and AI will definitely bring the experience of having looked at a lot of them. It'll be interesting to see, as AI gets better and better, will it be picking up these microerosions that are extremely sensitive, and and what does that mean for, you know, clinical relevance of them? So it'll be interesting because as it gets better and better, I wonder if this sensitivity might just produce, you know, more results that we then have to decide what to do with.
-Yeah, I agree that definitely imaging is important for diagnosis, specifically for our early patients, which is what we want to get them. And then, of course, having a good MRI result that we can trust is going to be very important. I think not only, of course, the radiologists need to have the education, but also ourselves as rheumatologists that are in charge of actually making the diagnosis, then it's going to be important to kind of understand what exactly is that we're looking for, or if we don't have those results, we're not sure, we definitely want to communicate with our radiologists.
So before we move on, just want to finally ask, of the three of you, who's using combination biologics? Know, yeah?
Yeah.
You've got one take. So yeah, yeah. I mean, I think that's all, yeah, everyone here. So maybe tell us about how... I think it'd be interesting to hear thoughts on where people think this is going.
Clearly, it's not going to be for everyone. Clearly, there are some people who will benefit. How do we pick the winners? How is it playing out in your practice?
So for me in particular, the most common situation when I find myself needing to use combination biologics is when I have patients with concomitant poorly controlled inflammatory bowel disease, you know? And so far, I've been doing very well so far, kind of like with as the evidence has been showing, the combination with the IL-twenty three inhibitors with the TNF. So, so far, that has been quite a success, but sometimes I've also been needing to use JAK in combination with IL-twenty three or TNF as well. And of course, we definitely need more data on safety. But so far, the data we have on safety seems pretty safe, so we'll have to see more.
Yeah, there was the study from the Spanish and the French groups here at ACR yesterday and today, I think replicates what we've seen at previous ACR and EULA, that generally it's quite safe. I think that's because of careful selection with these patients that's why it's turned out to be like this. And a lot of what we do is in combination with dermatologists or gastroenterologists. We're doing it within a combined clinic setting where we have decided that we would go for combination therapy. But I think it will become more common.
Fascinating how it's flipped from when we were in RA and TNF inhibitors and anachyma that didn't work out and then we for so long flipped away from this is completely prohibited on the label and now I feel like the move in spa has emboldened the rest of rheumatology and we haven't quite hit our safety barrier yet. It will be a very interesting one to see how it plays out. Anthony, tell me a little bit about what you saw that was good on the floor today.
So I think this ACR is focused on obesity and BMI. It's heavily, I can use the word, weighted on that. And so a lot of studies. But I was interested in thirteen oh five. And this is the bimekizumab data because it's a large data set.
What they did is they pulled the B optimal, B complete, and B vital. Now we know that in PSA, forty percent of people, PSA patients would be classified as obese or overweight. So in this study they had about one thousand patients who received 160mg Bisikizumab every four weeks. And they followed them up for three years, And the ACR50 was then divided up to whether they were the BMI of less than thirty or more than thirty five. And though people who had a BMI of greater than thirty five at one year, the ACR50 was 41 compared to the lighter group, which achieved fifty seven percent.
And at three years, that number remained the same. It didn't change after three years. We would expect that if you had achieved an ACL50, maybe you became more active, you could do more things. But in fact, it didn't change in that time. The percentages remained the same.
So it was static three years based on your initial BMI. And what's striking is the gap between those who had BMI of thirty five and those who had BMI of thirty. It was somewhere between a 17 percentage point difference between the two. Now of course, we will see the fifty two week data to get a PSA on the last day. But there is this whole we knew this for a long time that the higher your BMI, you poorer the response from biologics.
But this one shows you that not only that, you stay within that same class even three years down the line. So this calls for another approach that we would look at maybe in GLP ones in these people who have then achieved ACR50 that the combination would be a metabolic approach to treating them in terms of getting them further down on their tender, swollen joint counts.
And I mean this is, I guess, we've always seen this in our practice. I think now that we've got something that we can actively do about it, well I mean there's more options to think about what we can do about it, All of a sudden, I think we're starting to realize what we might be able to do. And I guess we're starting to be more concerned about the the... Where the causal relationship sits. So, Anthony, just speculate a little bit here for me.
It's, you know, this a safe space. It's only the entire internet listening to you. Just tell me what you think the breakdown how the causal relationships might sit here. You know, I think we're trying to I know we're trying to interpret things through post hoc analyses, registration data aren't necessarily meant to set up to answer these questions directly. But what's this relationship between weight and disease activity, pharmacotherapy activity?
How do you see it?
So what is quite clear from this data here today and also from the Together PSA data, which will be presented later in the conference, is that treating inflammation alone is not enough for us to not only achieve better joint outcomes, but also the weight loss. So when these people achieve ACR50, their weight still remains sometimes the reduction of the weight is not as significant as we think, that by getting them into good disease state that they may exercise more. So there is clearly a metabolic pathway here. So the incretins are doing something on adipocytes which we know are pro inflammatory. So it's not just the weight that is causing joint loading here but it's actually an inflammatory cascade here that I think that's at work.
Because if you look at the Tiguanip PSA data, now they didn't have a tisepatide alone arm in that study, but you could read from the combination versus isekizumab the alone that there's a 12 percentage point improvement. So every 100 patients, there are twelve other people who improve in terms of their joints just being on the extra GLP ones. So that's where we are going. So it's not just all inflammatory. And this brings up the whole thing that all these non inflammatory issues that we are discussing about difficult to treat, difficult to manage, While we are trying to understand all of that, I think this is here is potentially an avenue for us to go and explore in terms of the non inflammatory aspects of PSA.
Fascinating, fascinating stuff. Let's move on to the, well actually sorry, does anyone have any kind of, I mean this is something that's a very live thing in our practices. Eric, I mean, thinking about, I guess, how we're treating, our PSA patients, approaching our PSA patients. I mean, has this all changed the way that you counsel your patients and the way that you, I guess, approach this management approach? And I'm interested for Adela as well.
Very kind of different parts of the country, I think different perspectives are really important.
Absolutely. I think, you know, number one, I think just like gout, PSA is also a metabolic disorder. And so it is with hypertension, hyperlipidemia, diabetes, gout, PSA, I think are all in that same umbrella that we should think of cardiovascular risk just as we talked about with the first topic. It all is under one umbrella. And I think we need to not just focus on the joints and the skin, we need to think about it globally.
And number two, I think all this data and the Together PSA, and we now need to think about GLP-one or just weight reduction as disease modifying therapy. And I think that's true for osteoarthritis we've seen at this talk and for inflammatory arthritis and for nearly all of our conditions are touched on that addressing the weight is potentially disease modifying for a lot of these conditions.
And Adela, is that kind of, I guess, probably is pretty similar to... I I can imagine that it's pretty similar to the Paratroote.
I agree. And then the counseling is very important. I was actually talking to one of my colleagues when they came out of the session on the GLP and psoriatic arthritis, they were like, Counseling the patients, you may want to do it with a grain of salt. You may want to ask permission to the patient if you want to counsel them on obesity, which are, how often do you ask permission to counsel your patients? That was interesting to hear from that session.
And then I think it's important, and this is definitely something that is helpful to have because we do have that modifiable risk factor that not only causes inflammation and for so long was related to poor outcomes in those patients. Now we do have a tool to modify this risk factor. And of course, when we do see the weight loss, patients are a little bit more energetic, they have more ways to exercise. So that of course, changes a little bit of everything. It not only helps with their actual inflammation, but it also helps with, as Anthony was saying, the non inflammatory part, the depression, the neuroplastic pain, all of them.
Yeah, it's tricky. I mean, I think it's easy to offend in these situations and different people have very different perspectives to that. And if you get people offside over the first question, then you're not going to have much luck with the rest of the conversation. That opening is very important. So, I just want to talk a little bit about, you know, kind of in the same theme, but then a very much a right turn, talking a little bit about, I guess, what traditionally have been spa related therapies and how they're taking from PMR and GCA.
And there's there's some really good reasons for that. I guess, you know, we've been really focused on the Th one access previously and hence, tocilizumab, IL one... IL six, and I guess, you know, when we've kind of looked into IL-one kind of related therapies, but also I guess thinking about things like upadacitinib, where we know it's going to cover that. But then in recent times, there's been a bit of a shift. Well, I mean, it's always been there, but I think there's been a greater attention success breeds attention, to IL-seventeen, twelve twenty three focused therapies in the PMR and GCA space.
So one of the abstract in the PMR GCA abstract session, there are two, really interesting abstracts on that. Firstly, I think it was... It's a follow on data from the REPENSH study. A lot of us will be aware that REPENSH, secukinumab in, relapsing PMR came out early in the year. It's very much looking, it's looking quite good.
I think it's going to lead... You know, it's all going to lead to to real world use in the very near future, in multiple jurisdictions. What this looked at is, and I think this is always a question with, supposedly, phasic disease, sometimes phasic disease, like PMR, relapsing PMR, maybe, less phasic. What happens when you stop the therapy? And so in Replenish, after the first fifty two weeks, last act of therapy was at forty eight weeks, but you should still be on steady state at that point at fifty two weeks.
They stopped in both arms the placebo and the active therapy. What happened? Well, fifty percent of people flare in that situation. Shock horror, a relapsing PMI a chronic disease a lot of the time. But then, I guess, does secukinumab give you a legacy effect?
And there's a delta AUC between the two curves, there's a difference, but really it's possibly just maybe drug wearing off, maybe there's some limited legacy effect. I think we've got to dig into that a little bit more. Of course, ideally what we'd like to do is kind of hit people with a therapy and have an effect that goes beyond, but we may be stuck in a situation where we're giving people secukinumab in the long term, much as we would for RA and Axbar and PSA, and once upon a time people thought that they wouldn't thought the idea of giving ongoing therapy for PSA was ludicrous and we've come a long way since then. Know, all of sudden we're talking about all sorts of things. So the second part of that is actually in the same vein, ostokinamab in GCA.
And actually I remember some years ago watching our friend and colleague Richard Conway on the late breaking plenary stage talking about his study looking at patients who received osakimab for GCA. It looked very promising. There, there was a small, series from, from MassGen which looked a lot less promising. So in that context, the French have done a phase 2b investigated, initiated study because it's a patent randomized controlled trial, first time it's proper RCT data, and what you can see is that it's slow to kick in, you know, ustachianumab can be a bit slow to kick in, but there's definitely a wide gap between the con... Between the con...
The the placebo and the... And the isekindamab arms. So it's really interesting, in the context that THEA, c h e I a, study, which was geselkumab, the twenty three p nineteen inhibitor, in GCA was a bit of a bust, earlier this year. So I guess there's all sorts of questions. Is is IL twelve doing the heavy lifting?
Is there something different about this? Is it partially about study design? And will a phase three investigator initiated study actually happen? So let me kind of ask all three of you, first of all, are any of you using biologics at all for, PMR? And I guess this is a thing now, we've obviously got some options, we've got cirilimab in The US.
Right, and you know, and I love this because we also had like a great lecture from Mike Potman, of course, about this. And then there's still particularly the REPENISH and the saraholumab trial were all on relapsing disease. So technically, you really kind of have difficulty tapering the steroids. But in my clinical practice, these are patients that are already having so many comorbidities like diabetes, have very high risk for osteoporosis, and then do I want to wait to taper down the steroids that long? So having the access of biologic and having the option of starting biologic early and decrease the steroid burden for me is life changing, and it's also for my patients.
At the same time, having more than one option because I've had that patient where the patient, she did have a side effect to sorrelimab, and then I was like, What can I do now? But then now we do have other options that I can start my patients on. So definitely having that option of biologics for these patients is great.
Yeah, and I mean, you know, I think it is entirely possible we might have more options in the future in relapsing PMR. There's been a couple of things thrown around at this meeting, then I guess getting to your point as well, newly diagnosed, if we can get in there. Who knows, maybe it's all to do with yesterday we talked about generic tofacitinib and getting it from cost plus drugs and all the rest. Who knows what that might do? There's obviously some data there.
Great. So maybe we'll just quickly, time is getting upon us. Let's do a quick fire round around the grounds here, about some... Just an interesting thing that you saw out there. I'll start with, you, Eric.
Yeah. So yesterday, you you talked a lot about some of the new mechanisms for for myositis and particularly dermatomyositis. But I I think to zoom in on brepasinib, which is now FDA approved in The US, That is something that is available for us now, the TYK2 JAK inhibitor. There's a range of different posters on it, fifteen eighty four to fifteen eighty seven, and just a few quick hits from those. One of looked at skin.
Improvements began at week four, improvements of CDASI, itch scores, skin related quality of life. Another one on steroids, looking at the subgroup that three quarters of the patients entered the study on steroids. Those patients did well. They were able to taper the steroids. They looked at the subgroup that had interstitial lung disease.
One fifth of them had baseline ILD. They didn't specifically look at any ILD endpoints, so I can't comment on that. But it seemed to be safe in ILD patients. There wasn't any kind of signal for ILD progression, so I think definitely more information needed there. And then the fourth poster was looking at patient related outcomes, and the PROs looked favorable for functional disability, pain, and fatigue.
So I thought that was useful data for something that is now on the market for us.
Yeah, very exciting. Adela?
So I am going to go on that same note of the hot topic of GLP-one. So this one, this is abstract eighteen ninety eight, and in this study, the objective was to evaluate the association between GLP-one receptor agonists in patients with rheumatoid arthritis that were on DMARDs, particularly on methotrexate and TNF inhibitors, and they wanted to evaluate the risk of malignancy in five years. In specific malignancies that they were kind of high yield here were lung cancer and non Hodgkin lymphoma. This was a retrospective study using the TriNetX database, including over twenty four thousand patients with rheumatoid arthritis, and they did propensity score matching to make it even, so each cohort had over twelve thousand patients. And then in the study, it ended up showing that it seemed like patients that were on GLP-one, that had rheumatoid arthritis that were on GLP-one agonist had some decreased chances of having lung cancer and non Hodgkin lymphoma.
However, when I went a little bit more into it, definitely there was a lot of confounding. Specifically, we do know that malignancy at risk in patients with rheumatoid arthritis comes from disease and disease activity and smoking, so I didn't see mentioned about the smoking adjustment, but they didn't mention specifically the amount of smoking, active smoking, and of course they didn't include disease activity, so definitely a lot of confounding. Then, of course, a little bit of selection bias because patients that are on GLP-one agonist, probably they have more healthcare access or probably more monitored, things can be a little bit taken care of better than the ones that don't have the access. For me, was like, yeah, part of the hot topic, but I cannot make a conclusion on this yet.
Well, are very, I mean, they're very pertinent everyday questions that we need to figure out the answers for if we're going to start using a lot of GLP-1s and incretin therapy in RA, I guess, well. I think maybe one of the themes of of this meeting and others has been a lot of TriNetX. Some of it data, some of it's done well, some of it's done less well. I think this was, this was good, but I think at the same time it still just generates questions, more questions than answers sometimes. Anthony?
Yeah, these are hypothesis generating studies. They make us think about them, but I don't think we can definitely draw a line on them for the reasons that you described, Adela. They haven't matched for severity of smoking. I must talk about AI because no talk is complete without some AI. So I've gone for thirteen forty eight which is a nice study from Columbia where they looked over nearly twenty five years of their electronic health record and they used CHET GPT-four, approved, to see whether they could fish out of four point five million total number patients how many people had PSA.
And they gave them 27 features of PSA so that they could pick out how many people met CRISPR criteria. Now we always had this hype that we could use this to identify people for clinical trials or treatment. If you give them the guidelines they'll tell you how many people they have. So at best only forty three percent of these PSA patients they could say they met Casper criteria. They could pick up psoriasis.
They could pick up inflammatory arthritis. What they couldn't pick up is the disease activity. Only five percent of them had enough information for the dapsa and only five percent had joint counts. So the message is if you want to use AI in the future, we better record these things in our EHR. Otherwise, the data has got no use for us later on.
So that's, I think, the key message here. The AI can read your notes but depends on what's what's in your notes.
Absolutely, absolutely. And so my final one going along that same idea of a bit of AI and I know that Anthony's got one of these, you know, kind of... It's not quite in your cupboard, but you've got it in in the back of your office is Arthur Diana, the muscular skeletal ultrasound AI driven robot. Seen a little bit of this. It's been very interesting, how it's all played out in Europe.
This is the first independent evaluation that was done in Sweden, at Linkoping. What they did is they looked at 99 patients, 22 joints in wrist, hands, in the 28 joint count, and they 21, sorry, they got eighty six percent acquisition rate. So it's pretty good. I think the accuracy something that's yet to be determined. I think we look forward to seeing data around that.
Have you been having fun with yours, Anthony? Your machine?
We're having great fun. We are collecting data, but I think the performance is improving year on year. We've been to this, you've written on this as well in previous years, so I think it's certainly a help to us in terms of our decision making. It doesn't replace the rheumatologist, but it does help us gain time because we would otherwise be scanning these patients ourselves.
Absolutely, and time is what we all need. Speaking of which, we are at time. It has always been a pleasure. It's always a pleasure speaking to the three of you. Thank you very much for joining me, Anthony, Eric, Adela.
Have a great night. Thank you so much.
Thank very much.
Thanks. Thank you.

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.